Results 171 to 180 of about 21,820 (216)
Some of the next articles are maybe not open access.
Microbial Drug Resistance, 2022
We investigated the in vitro susceptibility of ceftazidime-avibactam (CZA) resistant Stenotrophomonas maltophilia to the associations aztreonam/amoxicillin-clavulanate (ATM-AMC) and ATM-CZA. Forty clinical isolates of S. maltophilia
Crémet, Lise +6 more
openaire +4 more sources
We investigated the in vitro susceptibility of ceftazidime-avibactam (CZA) resistant Stenotrophomonas maltophilia to the associations aztreonam/amoxicillin-clavulanate (ATM-AMC) and ATM-CZA. Forty clinical isolates of S. maltophilia
Crémet, Lise +6 more
openaire +4 more sources
The primary pharmacology of ceftazidime/avibactam: resistancein vitro
Journal of Antimicrobial Chemotherapy, 2023AbstractThis article reviews resistance to ceftazidime/avibactam as an aspect of its primary pharmacology, linked thematically with recent reviews of the basic in vitro and in vivo translational biology of the combination (J Antimicrob Chemother 2022; 77: 2321–40 and 2341–52).
Wright W Nichols +3 more
openaire +2 more sources
Ceftazidime/avibactam‐induced severe neutropenia: A case report
British Journal of Clinical Pharmacology, 2023AbstractCeftazidime/avibactam is an important option for the treatment of infections caused by multidrug‐resistant gram‐negative bacteria. Haematological abnormalities are rare adverse events. We describe a case of a 63‐year‐old male who developed severe neutropenia following exposure to ceftazidime/avibactam in the intensive care unit for the ...
Weifang Wu +3 more
openaire +2 more sources
Antimicrobial Agents and Chemotherapy, 2017 We determined imipenem, imipenem-relebactam, ceftazidime, and ceftazidime-avibactam MICs against 100 CRE isolates that underwent whole-genome sequencing.
Liang Chen +2 more
exaly +2 more sources
International Journal of Antimicrobial Agents, 2014
For an antibacterial agent to be considered for clinical studies in nosocomial pneumonia (NP), it should be active in the presence of pulmonary surfactant. Furthermore, owing to the common practice of treating such infections with more than one antibacterial agent, it should be free of antagonistic interactions with agents of other classes.
John, Dallow +4 more
openaire +2 more sources
For an antibacterial agent to be considered for clinical studies in nosocomial pneumonia (NP), it should be active in the presence of pulmonary surfactant. Furthermore, owing to the common practice of treating such infections with more than one antibacterial agent, it should be free of antagonistic interactions with agents of other classes.
John, Dallow +4 more
openaire +2 more sources
Ceftazidime/avibactam experience in tertiary hospital in Türkiye
Kastamonu Medical Journal, 2023Aims: Real-life experience with ceftazidime/avibactam in the treatment of multidrug-resistant Klebsiella pneumoniae is still limited. This retrospective study aims to evaluate the efficacy of ceftazidime/avibactam in the treatment of critically ill patients with infections due to carbapenem-resistant pathogens.
Alper Tahmaz, Ayşegül Seremet Keskin
openaire +1 more source
Ceftazidime/Avibactam: A New Antibiotic for Gram-Negative Infections
The Consultant Pharmacist, 2015To review the chemistry, pharmacology, microbiology, pharmacokinetics, pharmacodynamics, clinical efficacy, safety, dosing, and administration of ceftazidime/avibactam (CAZ/AVI).A search of PubMed using the terms "ceftazidime," "avibactam," "NXL104," and "AVE1330A" was performed. The manufacturer's website was also reviewed to further identify relevant
Elias B, Chahine +2 more
openaire +2 more sources